Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

f 2008 and if the results of this trial are positive, Cadence submitting a new drug application (NDA) for Omigard in the first half of 2009; data from the celgosivir Phase II extension protocol being available by the end of 2007; 4-week interim results from the Phase II viral kinetics combination study of celgosivir in approximately 10 treatment-naive patients in October 2007; submitting an IND in the US in the first quarter of 2008 for the future development of celgosivir; Cutanea Life Sciences completing the Phase II CLS001 rosacea clinical trial in 2007; our estimate of the probable royalties payable to the holders of the convertible royalty participation units; the Company continuing to advance its highest priority programs while operating within an annual burn rate of $11 million to $13 million; and the Company's financial resources being sufficient to fund operations into the third quarter of calendar 2008.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: Cadence's ability to enroll sufficient patients to complete the Omigard CLIRS trial; the adequacy of the CLIRS trial design to generate data that are deemed sufficient by regulatory authorities to support potential regulatory filings, including an NDA, for Omigard; our ability to manage licensing opportunities; our ability to initiate, fund and complete non-clinical studies, clinical studies, manufacturing and all ancillary activities within our expected timelines; our partner Cutanea Life Sciences completing a Phase II CLS001 rosacea clinical trial in 2007; to and future expense levels being within our current expectations.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and other factors including: dependence on c
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Texas Governor Rick ... Texas A&M Health Science Center CEO Brett Giroir, ... Health and Human Services (HHS), State of Texas ... pandemic influenza vaccine manufacturing facility in Bryan, Texas, ... for the Texas A&M Biocorridor – a rapidly ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Industry Report, 2014-2017" report to their offering. ... can differentiate into specialized cells and can divide (through ... can be applied to treatment of cardiovascular diseases, leukemia ... damage or lesion of liver, kidney and other parenchymal ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Human Albumin Industry Report 2014" report ... Albumin Industry Report 2014 is a professional and in-depth ... albumin industry. The report provides a basic ... industry chain structure. The human albumin market analysis is ...
(Date:9/18/2014)... Leatherwood Plastics has selected Vycom’s ... stay competitive in the semiconductor, clean room and ... impact product quality and productivity, according to Dwight ... in 1980 in Lewisville, TX, Leatherwood Plastics ... left the business. Much of Leatherwood’s equipment building ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
... OAKS, Calif., Nov. 1, 2010 Amgen (Nasdaq: ... Miletich, M.D., Ph.D., will urge members of a U.S. Food ... for biosimilars to establish approval standards that ensure patient safety ... and sound policy will follow," Dr. Miletich said.  "Amgen believes ...
... N.J., Nov. 1, 2010 PharmaNet Development Group, Inc., ... biotechnology, generic drug and medical device companies, today announced ... topics during the 9th Annual Partnerships in Clinical Trials ... in Vienna, Austria.   At the conference, ...
... today the company will present the results of a Week-24 ... in treatment-naive patients with chronic genotype 1 hepatitis C virus ... for the Study of Liver Diseases (AASLD) in Boston, MA., ... late-breaker oral presentation on Monday, November 1.   ...
Cached Biology Technology:Amgen to Provide Testimony at FDA Hearing on Biosimilars 2Amgen to Provide Testimony at FDA Hearing on Biosimilars 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 4PharmaNet Development Group Experts to Share Insights at the 9th Annual Partnerships in Clinical Trials Conference in Vienna 2Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 2Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 3Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 4
(Date:9/18/2014)... probably the ultimate form of camouflage: you don,t just ... strategy is not as uncommon as you might think. ... USA, explains that the larval life stages of many ... of the anatomy that most creatures cannot make transparent. ... to shield each individual eye unit with an opaque ...
(Date:9/18/2014)... Clownfish spend their entire lives nestling in the protective ... as babies they sometimes travel hundreds of kilometres across ... by reef fish has been predicted, this is the ... between distant populations has been observed. , Dr Steve ... at the University of Exeter, and colleagues from the ...
(Date:9/17/2014)... the creation of the Santa Ana Wildfire Threat Index ... potential of the powerful, hot, dry Santa Ana wind, ... index was introduced Sept. 17 by the U.S. Forest ... and Electric. , The index includes four classification levels ... to help fire agencies and other emergency responders, the ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... close relative of the Formosan "super termite" that's gnawing ... established in South Florida, according to University of Florida ... in tropical areas such as Brazil and the West ... to Florida until now," said Nan-Yao Su, a professor ...
... geneticist Harvey D. Blackburn is responsible for collecting and ... semen and embryos -- to make sure there's enough ... of his collection deals with important livestock such as ... the collections Blackburn, who is the coordinator of the ...
... has found that one of the cell's largest families ... regulate the development of nerve cells, also controls nerve ... learning and memory. These findings, the first to link ... appear in the May issue of Nature Cell Biology, ...
Cached Biology News:Cousin of Asian super termite invades Florida 2Making Sure Sacred Sheep Don't Become Extinct 2Structure-building cell signals also may influence learning and memory 2Structure-building cell signals also may influence learning and memory 3